Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Amgen
Age
18–any
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Pathologically confirmed adenocarcinoma of the prostate
Radiographic evidence of metastatic disease
Progressive disease meeting at least one of the following criteria:
1. a sequence of at least 2 rising PSA values measured at a minimum of 1 week apart with a 2 ng/mL minimum starting value, or
2. progression according to RECIST criteria for measurable lesions, or
3. appearance of 2 or more new lesions on bone scan.
History of prior taxane-based chemotherapy for metastatic prostate cancer
For patients without a history of surgical castration, continued GnRH analog administration is required
ECOG Performance status of 0 or 1
Life expectancy ≥ 3 months
You may not be if
Treatment with external beam radiotherapy ≤ 14 days before enrollment or radiopharmaceutical ≤8 weeks
≤ 4 weeks since receipt of most recent prior chemotherapy, non-GnRH analog hormonal therapy (except for continuing corticosteroids) or other systemic therapy to treat prostate cancer and \<6 weeks since receipt of prior bevacizumab.
Known CNS metastases (epidural disease is allowed if it has been treated and there is no progression in the treated area).
Significant cardiovascular disease
LVEF \< 50% by MUGA or ECHO
Treatment of infection with systemic anti-infectives within 7 days before enrollment (with the exception of uncomplicated urinary tract infection)
Concurrent or prior (within 7 days of enrollment) anticoagulation therapy, except that use of low dose coumarin-type anticoagulants or heparins for prophylaxis against central venous catheter thrombosis is allowed
Major surgical procedure ≤30 days before enrollment or not yet recovered from prior major surgery
Presence of peripheral edema \> Grade 2
Known positive test for HIV, hepatitis C, chronic or active hepatitis B
Serious or non-healing wound
Unable to begin protocol specified treatment within 7 days after enrollment
Other investigational procedures are excluded.
Clareo Health | AMG 102 in Combination With Mitoxantrone and Prednisone in Subjects With Previously Treated Castrate Resistant Prostate Cancer
